Drug intelligence / Profile preview

amoxicillin + clarithromycin + metronidazole

Development stage: Unknown
Lead developer: GSK
Modality: Small Molecules
Administration: Oral

Overview

This is a triple antibiotic combination therapy used primarily for the eradication of Helicobacter pylori (H. pylori) infection. It is typically administered alongside a proton pump inhibitor (PPI) such as omeprazole or lansoprazole to form a quadruple therapy regimen. This combination works by targeting H. pylori through multiple mechanisms to overcome potential antibiotic resistance. The treatment duration is typically 5-14 days, with 7 days being common in many protocols.

Targets

PBP1 (Penicillin-binding protein 1)NeuraminidaseBacterial 50S ribosomal subunit

Beyond the preview

Go deeper on amoxicillin + clarithromycin + metronidazole.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on amoxicillin + clarithromycin + metronidazole.

Explore the full profile